KMD Biomarkers Diagnostics Inc. has developed a test to analyze metabolic profiles of urine and deliver accurate, early-stage detection of breast cancer.
12% of ALL women will develop invasive breast cancer in their lifetime. Over 40,000 women are expected to die from breast cancer in 2015 alone. Additionally, high false positive and false negative diagnosis further complicates therapy decisions or lead to unnecessary invasive procedures at an annual cost of over 4 billion dollars. Early and accurate diagnosis is key to managing the disease. KMD’s breast cancer screening test will make that possible.
KMD’s test will allow us to detect breast cancer non-invasively and painlessly with almost no false positives or negatives and at an earlier stage than existing methods. We are a team of scientists and entrepreneurs who have launched a global campaign to fund research into non-invasive, accurate and sensitive ways to detect disease early to allow physicians to choose an appropriate therapy or monitor the disease through active surveillance or watchful waiting.
KMD’s ultimate ability to detect early and accurately diagnose breast cancer with a single sample from a patient will revolutionize our approach to healthcare by incorporating cost-effective and health-effective preventive measures and offering personalized recommendations based on individual patients’ needs and preferences.
